VX15-440-101: A Phase 2, Randomized, Double-blind, Contr

Project: Research project

Project Details

Description

VX15-440-101: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis
StatusFinished
Effective start/end date11/6/161/1/20

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.